Navigation Links
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Date:6/9/2008

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.

The poster presentation, entitled "Trodusquemine (MSI-1436) Improves Glucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance" concluded that treatment with MSI-1436 leads to significant improvements in insulin sensitivity as well as lower HbA1C levels and weight loss in animal models of diabetes. In one study, it was reported that four weekly treatments of MSI-1436 administered to ob/ob mice induced significant and dose-dependent reductions in HbA1C levels and body weight. In a separate study, treatment of db/db mice with a single dose of MSI-1436 demonstrated a significant improvement in oral glucose tolerance (OGTT) within 24 hours of dosing, and prior to any significant change in body weight. The scientists concluded that MSI-1436 may be useful for the treatment of type 2 diabetes and obesity in humans based on the marked improvements in insulin sensitivity, HbA1C, fasting blood glucose and body weight seen in these studies.

"All of our preclinical work continues to provide very encouraging support for our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes and obesity," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We have recently completed dosing in our second Phase 1a study of MSI-1436 in patients with type 2 diabetes and expect to initiate a planned Phase 1b (ascending multiple dose) stud
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
4. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
5. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)...  Quest Diagnostics (NYSE: DGX ), the ... that its Board of Directors has elected Jeffrey M. ... 1, 2014. Including Dr. Leiden, the Board has 11 ... and CEO of Vertex Pharmaceuticals.   Dr. Leiden has ... in the pharmaceutical and biotechnology industries as well as ...
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical ... on women,s healthcare and pain management, announced today ... The round was led by Longitude Capital ... Point Capital. Other current investors that participated in ...
... Center Association, JWCH Institute and the County of Los ... Community Health Downtown Los Angeles, a state-of-the-art medical facility ... homeless and low-income people in and around Skid Row. ... Street, is expected to meet the healthcare needs of ...
Cached Medicine Technology:Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 2Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually 3
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... spike between 2008 and 2009, analysis finds , SATURDAY, ... appear to be on the rise, warns the American ... and baseball/softball are the main culprits. , The cautionary ... as they transpired between 2008 and 2009, based on ...
... drinkers were 39% less likely to get these malignancies ... help protect against head and neck cancers, a new ... the International Head and Neck Cancer Epidemiology consortium. They ... a day) were 39 percent less likely to develop ...
... is part of being a good dad, expert suggests , ... dads unwrap their new ties and other tokens of gratitude, ... kind of gift: a promise that they,ll watch their health, ... On average, men die younger than women and are more ...
... radiation not always ideal for many with low risk ... -- For patients with prostate cancer that has a ... "watchful waiting," may be a suitable treatment option, according ... of how (or whether) to treat localized prostate cancer ...
... ... ... Technologies , the leading independent provider of search software integration services announced today an ... for the Folio and NXT professional publishing products. The Folio product family includes Folio ...
... Recent research has shown increase in sexual satisfaction, if ... A U.S. Food and Drug Administration advisory panel on ... the "female Viagra" for premenopausal women with a diminished ... to the antidepressant family and affects serotonin and other ...
Cached Medicine News:Health News:Bump in Head Injury Numbers Linked to Summer Play 2Health News:On Father's Day, Give Dad Gift of Health 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 3
... Microvolume technology , The ADVIA 1650 has ... as 2 L/test), reagent consumption (as low ... L/hour) - thus maximizing management efficiency. , ... cycle and system throughput of up to ...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
Medicine Products: